CPT: 83520
Print Share

Expected Turnaround Time

7 - 8 days

Related Information

Related Documents

Specimen Requirements


Serum or plasma


0.3 mL

Minimum Volume

0.1 mL (Note:This volume does not allow for repeat testing.)


Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube


Separate serum or plasma from cells and transfer to an appropriate tube.

Storage Instructions


Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Nonserum or non-EDTA plasma received

Test Details


This test is used to measure the level of adiponectin in serum or plasma.


This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Enzyme-linked immunosorbent assay (ELISA)

Reference Interval

See table.

Age (y)

Range (mL)

0 to 7


8 to 9


10 to 11


12 to 13


14 to 15


16 to 19


20 to 29


30 to 39


40 to 49


50 to 59


60 to 100


Additional Information

Adiponectin is the most abundant peptide hormone secreted by adipocytes.1-3 Other cell types such as skeletal and cardiac myocytes and endothelial cells can produce lesser amounts of this protein. Adiponectin has a short half-life of 45-75 minutes despite its minimal degradation during circulation. Its clearance is predominantly by the liver but can also bind pancreatic beta cells and certain heart and kidney cell types.1 Adiponectin participates in glucose regulation but also exerts anti-inflammatory, anti-atherogenic and cardioprotective effects as well as effects on lipid metabolism and fatty acid oxidation.1,4 Adiponectin directly acts on the liver, skeletal muscle, and vasculature through insulin sensitization and anti-inflammatory/anti-atherogenic effects.1 Adiponectin increases insulin secretion from the pancreas and mediates insulin sensitivity in skeletal muscle.1,3,5 Adiponectin enhances basal glucose and insulin-stimulated glucose uptake in adipose tissues.1,3,4 Adiponectin increases insulin sensitivity and down-regulates gluconeogenesis in the liver while activating fatty acid oxidation.1,3 Studies have shown that adiponectin decreases inflammation in macrophages, endothelial tissue, muscle, and epithelial cells.3 There is evidence that adiponectin prevents the production of reactive oxidative species and promotes down-regulation of inflammation.3 Moreover, it has been shown to inhibit CRP secretion and suppression of pathways involving NF-kB signaling and TNF-Alpha.3

Obese patients tend to have decreased serum levels of adiponectin. Various cross-sectional studies have established an inverse relationship between adiponectin serum levels and BMI and fat mass.6-8 Adiponectin levels are increased in extremely lean patients suffering from conditions such as anorexia nervosa.7 Weight loss through means such as diet and exercise and bariatric surgery have resulted in increased plasma levels of adiponectin in patients.7 Diminished serum adiponectin levels is a feature in pathologies such as gestational diabetes.7,9 Strong genetic associations between adiponectin levels and insulin resistance have also been established5 and low levels of it predict future onset of insulin resistance.7,10 Adiponectin levels demonstrate an inverse correlation with adiposity and proinflammatory cytokines in patients suffering from metabolic syndrome.11-14 Low levels of adiponectin predict a higher incidence of adverse cardiovascular events such as myocardial infarctions and atherosclerosis.14,15

Recently, adiponectin has shown to exhibit activity in functions of cell proliferation, where it has been shown to counter cell growth and induce apoptosis.14 It is also noteworthy, however, that several recent studies have also demonstrated adiponectin to have anti apoptotic and proliferative roles.14 Accumulating evidence suggest that adiponectin is implicated in the pathogenesis of several malignancies.13,16,17 Several observational studies showed that low adiponectin levels are associated with higher risk for breast, cervical, endometrial, ovarian and prostate cancer.13,16,17 A relationship between adiponectin and the aggressiveness of some of these tumors has also been reported.13,16-18


1. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 2017 Jun 21;18(6):1321.28635626
2. Scherer PE. Adiponectin: basic and clinical aspects. Preface. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1)1-2.24417940
3. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012 Sep;55(9):2319-2326.22688349
4. Nguyen TMD. Adiponectin: Role in Physiology and Pathophysiology. Int J Prev Med. 2020 Sep 3;11:136.33088464
5. Liu Y, Sweeney G. Adiponectin action in skeletal muscle. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):33-41.24417944
6. Nielsen MB, Çolak Y, Benn M, Nordestgaard BG. Low Plasma Adiponectin in Risk of Type 2 Diabetes: Observational Analysis and One- and Two-Sample Mendelian Randomization Analyses in 756,219 Individuals. Diabetes. 2021 Nov;70(11):2694-2705.34426507
7. Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005 Feb;257(2):167-175.15656875
8. Nielsen MB, Çolak Y, Benn M, Nordestgaard BG. Causal Relationship between Plasma Adiponectin and Body Mass Index: One- and Two-Sample Bidirectional Mendelian Randomization Analyses in 460 397 Individuals. Clin Chem. 2020 Dec 1;66(12):1548-1557.33106853
9. Bao W, Baecker A, Song Y, Kiely M, Liu S, Zhang C. Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review. Metabolism. 2015 Jun;64(6):756-764.25749468
10. Mather KJ, Goldberg RB. Clinical use of adiponectin as a marker of metabolic dysregulation. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):107-117.24417950
11. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014 Jun 23;13:103.24957699
12. Fu Y. Adiponectin signaling and metabolic syndrome. Prog Mol Biol Transl Sci. 2014;121:293-319.24373241
13. Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Rev Endocr Metab Disord. 2014 Jun;15(2):157-167.24019064
14. Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913.25110685
15. Hao G, Li W, Guo R, Yang JG et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013 May;228(1):29-35.23489345
16. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012 Aug;33(4):547-594.22547160
17. Tsankof A, Tziomalos K. Adiponectin: A player in the pathogenesis of hormone-dependent cancers. Front Endocrinol (Lausanne). 2022 Oct 6;13:1018515.36277714
18. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010 Jan;56(1):34-43.19910504


Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: The missing link between insulin-resistance and obesity. Diabetes Metab. 2008 Feb;34(1):2-11.18093861
Goldstein BJ, Scalia RG, Ma XI. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009 Jan;6(1):27-35.19029992
Guerre-Millo M. Adiponectin: An update. Diabetes Metab. 2008 Feb;34(1):12-18.18069030
Lee B, Shao J. Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2014 Jun;15(2):149-156.24170312
Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2009 Jul 8; 302(2):179-188.19584347
Menzaghi C, Trischitta V. The Adiponectin Paradox for All-Cause and Cardiovascular Mortality. Diabetes. 2018 Jan;67(1):12-22.29263167
Orlando A, Nava E, Giussani M, Genovesi S. Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents. Int J Mol Sci. 2019 Jun 30;20(13):3228.31262082
Parida S, Siddharth S, Sharma D. Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease. Int J Mol Sci. 2019 May 22;20(10):2519.31121868
Polito R, Di Meo I, Barbieri M, Daniele A, Paolisso G, Rizzo MR. Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review. Int J Mol Sci. 2020 Dec 4;21(23):9255.33291597
Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: State of the art? Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1655-H1663.17142348
Turer AT, Scherer PE. Adiponectin: Just Along for the Ride? Circ Res. 2016 Jul 22;119(3):407-408.27458194
Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012 Sep;55(9):2319-2326.22688349
Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008 Jan;51(1):8-14.17998473


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
004650 Adiponectin 47828-9 004651 Adiponectin ug/mL 47828-9

For Providers

Please login to order a test

Order a Test

© 2023 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2023, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at